Supriya Lifescience News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Supriya Lifescience Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Supriya Lifescience Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news and updates on Supriya Lifescience from all sources in a single place.

Supriya Lifescience Ltd.

06 Jan 2026

735.00

-0.49%

Company Update

Supriya Lifescience Ltd - 543434 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for quarter ended December 31, 20205 is enclosed.

pdf

Supriya Lifescience Ltd.

30 Dec 2025

735.00

-0.49%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation on Credit Rating to the Company is enclosed.

pdf

Supriya Lifescience Ltd.

28 Dec 2025

735.00

-0.49%

SAST

Supriya Lifescience Ltd - 543434 - Closure of Trading Window

BSE India

Intimation for Closure of Trading Window for declaration of the Unaudited Financial Results for quarter and nine months ending on December 31, 2025. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

26 Nov 2025

735.00

-0.49%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on Tuesday, December 2, 2025 as per details attached herewith. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

18 Nov 2025

735.00

-0.49%

Earnings Call

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2025, is enclosed herewith. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

18 Nov 2025

735.00

-0.49%

Strong sequential rebound with broad-based growth; exports and Module E ramp-up drive performance

Accumulate: Supriya Lifescience Ltd.

Recommendation Target

Deven Choksey

We expect growth momentum to sustain over the coming quarters, supported by steady demand across regulated markets, scale-up of the Module E facility, and a stronger mix from high-value therapies.